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background:  Familial Hypercholesterolemia (FH) is a genetic disorder that leads to substantially elevated levels of low-density lipoprotein 
cholesterol (LDL-C). The 2013 ACC/AHA lipid guidelines denote an LDL-C level >=190 mg/dL (suggestive of FH) as an independent 
high-risk feature. While it is estimated that over 600,000 individuals in the U.S. have FH, fewer than 10% of these have been formally 
diagnosed.
Methods:  As the only active FH registry in the US, the CASCADE-FH Registry, an initiative of the FH Foundation (FHF), utilizes a novel, 
dual-pathway enrollment design: 1) Enrollment of formally diagnosed FH patients by a clinical provider, with abstraction of clinical data from 
medical records; 2) Self-enrollment and data entry via an online portal for participants meeting LDL criteria consistent with FH. Followup 
data will be captured annually.
Results:  A total of 1,236 FH patients have been enrolled (165 from the online portal and 1,071 from 11 specialty sites). The median 
pretreatment LDL-C (IQR) was 249 mg/dL (211-310 mg/dL). Just over half were treated with high-intensity statins. LDL apheresis is 
currently being used in 7.2% of patients. Updated data from additional patients and longitudinal follow-up data will be available for 
presentation at the ACC sessions in March 2015.
conclusion:  The CASCADE-FH Registry is a unique partnership between FH patients, the FH Foundation and clinical researchers to 
raise awareness of the need for improved diagnosis and treatment of FH in contemporary practice.
 
